Research in people with psychosis risk syndrome: A review of the current evidence and future directions

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 51, Issue 4, 2010, Pages 390-431

  Correll, Christoph U ^a,b,c   Hauser, Marta ^a,d   Auther, Andrea M ^a   Cornblatt, Barbara A ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; DSM V; Early intervention; Early recognition; Prodrome; Psychosis; Risk syndrome; Schizophrenia

Indexed keywords

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FORECASTING; HUMAN; PSYCHIATRY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW; RISK FACTOR;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FORECASTING; HUMANS; PSYCHIATRY; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 77949404965     PISSN: 00219630     EISSN: 14697610     Source Type: Journal    
DOI: 10.1111/j.1469-7610.2010.02235.x     Document Type: Article

References (312)

1. Ahlemeyer, B. Krieglstein, J. (2003). Neuroprotective effects of Ginkgo biloba extract. Cell and Molecular Life Sciences, 60, 1779 1792.
2. Allen, A.J., Griss, M.E., Folley, B.S., Hawkins, K.A. Pearlson, G.D. (2009). Endophenotypes in schizophrenia: A selective review. Schizophrenia Research, 109, 24 37.
3. Allen, T.B. McEvoy, J.P. (2002). Galantamine for treatment-resistant schizophrenia. American Journal of Psychiatry, 159, 1244 1245.
4. Amminger, G., Leicester, S., Yung, A.R., Phillips, L.J., Berger, G.E., Francey, S.M., Yuen, H.P. McGorry, P.D. (2006). Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophrenia Research, 84, 67 76.
5. Amminger, G., Schaefer, M.R., Papageorgiou, K., Becker, J., Mossaheb, N., Harrigan, S.M., McGorry, P.D. Berger, G. (2007). Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: A double-blind randomized, placebo-controlled treatment study. Schizophrenia Bulletin, 33, 418 419.
6. Amminger, G.P., Schaefer, M.R., Papageorgiou, K., Harrigan, S., McGorry, P.D. Berger, G. (2008). Indicated prevention of psychotic disorders with long-chain omega-3 fatty acids: A randomized, placebo-controlled trial. Schizophrenia Research, 102, S252.
7. Andreasen, N 1987). The Comprehensive Assessment of Symptoms and History (CASH) interview. Ames, IA:University of Iowa.
8. Angelucci, F., Aloe, L., Iannitelli, A., Gruber, S.H. Mathé, A.A. (2005). Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. European Neuropsychopharmacology, 15, 311 317.
9. Angelucci, F., Mathé, A.A. Aloe, L. (2000). Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. Journal of Neuroscience Research, 60, 783 794.
10. Antonelli, T., Ferraro, L., Hillion, J., Tomasini, M.C., Rambert, F.A. Fuxe, K. (1998). Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport, 9, 4209 4213.
11. Areosa, S.A. Sherriff, F 2003). Memantine for dementia. Cochrane Database Systems Review (1,3 CD003154.
12. Auther, A.M., et al. 2008). Presented at the 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May.
13. Bai, O., Chlan-Fourney, J., Bowen, R., Keegan, D. Li, X.M. (2003). Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research, 71, 127 131.
14. Bai, O., Wei, Z., Lu, W., Bowen, R., Keegan, D. Li, X.M. (2002). Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. Journal of Neuroscience Research, 69, 278 283.
15. Bai, O., Zhang, H. Li, X.M. (2004). Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Research, 1010, 81 86.
16. Banerjee, S.P., Zuck, L.G., Yablonsky-Alter, E. Lidsky, T.I. (1995). Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport, 6, 2500 2504.
17. Bareyre, F.M., Saatman, K.E., Raghupathi, R. McIntosh, T.K. (2000). Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats. Journal of Neurotrauma, 17, 1029 1039.
18. Bauer, M., Juckel, G., Correll, C.U., Leopold, K. Pfennig, A. (2008). Diagnosis and treatment in the early illness phase of bipolar disorders. European Archives of Psychiatry and Clinical Neuroscience, 258 (Suppl. 5 50 4.
19. Bechdolf, A 2009). http://clinicaltrial.gov/ct2/results?term= prodrome+AND+schizophrenia, accessed August 23, 2009.
20. Bechdolf, A., Pukrop, R., Kohn, D., Tschinkel, S., Veith, V., Schultze-Lutter, F., Ruhrmann, S., Geyer, C., Pohlmann, B. Klosterkötter, J. (2005a). Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 79, 137 143.
21. Bechdolf, A., Veith, V., Schwarzer, D., Schormann, M., Stamm, E., Janssen, B., Berning, J., Wagner, M. Klosterkötter, J. (2005b). Cognitive-behavioral therapy in the pre-psychotic phase: An exploratory study. Psychiatry Research, 136, 251 255.
22. Bechdolf, A., Wagner, W., Ruhrmann, S., Harrigan, S., Veith, V., Pukrop, R., Brockhaus-Dumke, A., Berning, J., Janssen, B., Decker, P., Bottlender, R., Maurer, K., Moller, H.J., Gaebel, W., Hafner, H., Maier, W. Klosterkötter, J. (2008). CBT in the early initial prodromal state: 24-months results. Schizophrenia Research, 102, S2, S33.
23. Bechdolf, A., Wagner, M., Veith, V., Ruhrmann, R., Janssen, B., Bottlender, R., Moeller, H.J., Gaebel, W., Maier, W. Klosterkötter, J. (2006). A randomized controlled multicenter trial of cognitive behavior therapy in the early initial prodromal state of psychosis. Schizophrenia Research, 86, S1, S96.
24. Bell, R.Q. (1992). Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry, 55, 370 381.
25. Berger, G., Dell'Olio, M., Amminger, P., Cornblatt, B., Phillips, L., Yung, A., Yan, Y., Berk, M. McGorry, P. (2007a). Neuroprotection in emerging psychotic disorders. Early Intervention in Psychiatry, 1, 114 127.
26. Berger, G.E., Proffitt, T.M., McConchie, M., Yuen, H., Wood, S.J., Amminger, G.P., Brewer, W. McGorry, P.D. (2007b). Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 68, 1867 1875.
27. Berger, G.E., Smesny, S. Amminger, G.P. (2006). Bioactive lipids in schizophrenia. International Review of Psychiatry, 18, 85 98.
28. Berger, G.E., Wood, S.J., Wellard, R.M., Proffitt, T.M., McConchie, M., Amminger, G.P., Jackson, G.D., Velakoulis, D., Pantelis, C. McGorry, PD 2008). Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology, 33, 2467 2473. Erratum in: Neuropsychopharmacology, 2009, 34, 535.
29. Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., Ording-Jespersen, S., Little, J., Conus, P., Cuenod, M., Do, K.Q. Bush, A.I. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64, 361 368.
30. Bora, E., VeznedarogLu, B. Kayahan, B. (2005). The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clinical Neuropharmacology, 28, 139 141.
31. Borgwardt, S.J., McGuire, P.K., Aston, J., Berger, G., Dazzan, P., Gschwandtner, U., Pfluger, M., D'Souza, M., Radue, E.W. Riecher-Rossler, A. (2007b). Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. British Journal of Psychiatry, 51 (Suppl. s69 s75.
32. Borgwardt, S.J., Riecher-Rossler, A., Dazzan, P., Chitnis, X., Aston, J., Drewe, M., Gschwandtner, U., Haller, S., Pflüger, M., Rechsteiner, E., D'Souza, M., Stieglitz, R.D., Radu, EW. McGuire, P.K. (2007a). Regional gray matter volume abnormalities in the at risk mental state. Biological Psychiatry, 61, 1148 1156.
33. Bramon, E., Shaikh, M., Broome, M., Lappin, J., Bergé, D., Day, F., Woolley, J., Tabraham, P., Madre, M., Johns, L., Howes, O., Valmaggia, L., Pérez, V., Sham, P., Murray, R.M. McGuire, P. (2008). Abnormal P300 in people with high risk of developing psychosis. Neuroimage, 41, 553 560.
34. Brewer, W.J., Edwards, J., Anderson, V., Robinson, T. Pantelis, C. (1996). Neuropsychological, olfactory, and hygiene deficits in men with negative symptom schizophrenia. Biological Psychiatry, 40, 1021 1031.
35. Brewer, W.J., Francey, S.M., Wood, S.J., Jackson, H.J., Pantelis, C., Phillips, L.J., Yung, A.R., Anderson, V.A. McGorry, P.D. (2005). Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. American Journal of Psychiatry, 162, 71 78.
36. Brewer, W.J., Francey, S.M., Yung, A.R., Velakoulis, D., McGorry, P.D., Singh, B., Copolov, D. Pantelis, C. (2003a). Cognitive and olfactory deficits: Course from high risk to first-episode psychosis. Schizophrenia Research, 29, 54 55.
37. Brewer, W.J., Wood, S.J., McGorry, P.D., Francey, S.M., Phillips, L.J., Yung, A.R., Anderson, V., Copolov, D.L., Singh, B., Velakoulis, D. Pantelis, C. (2003b). Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. American Journal of Psychiatry, 160, 1790 1794.
38. Brewer, W.J., Wood, S.J., Phillips, L.J., Francey, S.M., Pantelis, C., Yung, A.R., Cornblatt, B. McGorry, P.D. (2006). Generalized and specific cognitive performance in clinical high-risk cohorts: A review highlighting potential vulnerability markers for psychosis. Schizophrenia Bulletin, 32, 538 555.
39. Brockhaus-Dumke, A., Schultze-Lutter, F., Mueller, R., Tendolkar, I., Bechdolf, A., Pukrop, R., Klosterkötter, J. Ruhrmann, S. (2008). Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biological Psychiatry, 64, 376 384.
40. Brockhaus-Dumke, A., Tendolkar, I., Pukrop, R., Schultze-Lutter, F., Klosterkötter, J. Ruhrmann, S. (2005). Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophrenia Research, 73, 297 310.
41. Cadenhead, K.S., Light, G.A., Shafer, K.M. Braff, D.L. (2005). P50 suppression in individuals at risk for schizophrenia: The convergence of clinical, familial, and vulnerability marker risk assessment. Biological Psychiatry, 57, 1504 1509.
42. Cahn, W., Hulshoff Pol, H.E., Lems, E.B., van Haren, N.E., Schnack, H.G., van der Linden, J.A., Schothorst, P.F., van Engeland, H. Kahn, R.S. (2002). Brain volume changes in first-episode schizophrenia: A 1-year follow-up study. Archives of General Psychiatry, 59, 1002 1010.
43. Calabrese, F., Molteni, R., Maj, P.F., Cattaneo, A., Gennarelli, M., Racagni, G. Riva, M.A. (2007). Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology, 32, 2351 2359.
44. Cannon, M., Jones, P.B. Murray, R.M. (2002). Obstetric complications and schizophrenia: Historical and meta-analytic review. American Journal of Psychiatry, 159, 1080 1092.
45. Cannon, T.D., Cadenhead, K., Cornblatt, B., Woods, S.W., Addington, J., Walker, E., Seidman, L.J., Perkins, D., Tsuang, M., McGlashan, T. Heinssen, R. (2008). Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Archives of General Psychiatry, 65, 28 37.
46. Cannon, T.D., Cornblatt, B. McGorry, P. (2007). The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophrenia Bulletin, 33, 661 664.
47. Cannon, T.D., van Erp, T.G., Bearden, C.E., Loewy, R., Thompson, P., Toga, A.W., Huttunen, M.O., Keshavan, M.S., Seidman, L.J. Tsuang, M.T. (2003). Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions. Schizophrenia Bulletin, 29, 653 669.
48. Chen, B., Dowlatshahi, D., MacQueen, G.M., Wang, J.F. Young, L.T. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry, 50, 260 265.
49. Chen, G., Zeng, W.Z., Yuan, P.X., Huang, L.D., Jiang, Y.M., Zhao, Z.H. Manji, H.K. (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry, 72, 879 882.
50. Chu, K., Jeong, S.W., Jung, K.H., Han, S.Y., Lee, S.T., Kim, M. Roh, J.K. (2004). Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. Journal of Cerebral Blood Flow and Metabolism, 24, 926 933.
51. Chua, W.L., de Izquierdo, S.A., Kulkarni, J. Mortimer, A. (2005). Estrogen for schizophrenia. Cochrane Database Systems Review, 19, CD004719.
52. Conus, P., Ward, J., Hallam, K.T., Lucas, N., Macneil, C., McGorry, P.D. Berk, M. (2008). The proximal prodrome to first episode mania - a new target for early intervention. Bipolar Disorder, 10, 555 565.
53. Conus, P., Ward, J., Lucas, N., Cotton, S., Yung, A.R., Berk, M. McGorry, P.D. (2010). Characterisation of the prodrome to a first episode of psychotic mania: Results of a retrospective study. Journal of Affective Disorders, Jan 18 [Epub ahead of print].
54. Corcoran, C.M., Kimhy, D., Stanford, A., Khan, S., Walsh, J., Thompson, J., Schobel, S., Harkavy-Friedman, J., Goetz, R., Colibazzi, T., Cressman, V. Malaspina, D. (2008). Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophrenia Research, 106, 286 293.
55. Cornblatt, B.A., Auther, A.M., Niendam, T., Smith, C.W., Zinberg, J., Bearden, C.E. Cannon, T.D. (2007a). Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophrenia Bulletin, 33, 688 702.
56. Cornblatt, B.A., Lencz, T. Kane, J.M. (2001). Treatment of the schizophrenia prodrome: Is it presently ethical? Schizophrenia Research, 51, 31 38.
57. Cornblatt, B.A., Lencz, T., Smith, C.W., Correll, C.U., Auther, A.M. Nakayama, E. (2003). The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophrenia Bulletin, 29, 633 651.
58. Cornblatt, B.A., Lencz, T., Smith, C.W., Olsen, R., Auther, A.M., Nakayama, E., Lesser, M.L., Tai, J.Y., Shah, M.R., Foley, C.A., Kane, J.M. Correll, C.U. (2007b). Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents Journal of Clinical Psychiatry, 68, 546 557.
59. Correll, C.U. Kane, J.M. (2004). The psychotic prodrome: How effective are early interventions? Advances in Schizophrenia and Clinical Psychiatry, 1, 2 10.
60. Correll, C.U., Lencz, T., Smith, C.W., Auther, A.M., Nakayama, E.Y., Hovey, L., Olsen, R., Shah, M., Foley, C. Cornblatt, B.A. (2005). Prospective study of adolescents with subsyndromal psychosis: Characteristics and outcome. Journal of Child and Adolescent Psychopharmacology, 15, 418 433.
61. Correll, C.U., Penzner, J.B., Lencz, T., Auther, A., Smith, C.W., Malhotra, A.K., Kane, J.M. Cornblatt, B.A. (2007a). Early identification and high-risk strategies for bipolar disorder. Bipolar Disorders, 9, 324 338.
62. Correll, C.U., Penzner, J.B., Frederickson, A.M., Richter, J.J., Auther, A.M., Smith, C.W., Kane, J.M. Cornblatt, B.A. (2007b). Differentiation in the preonset phases of schizophrenia and mood disorders: Evidence in support of a bipolar mania prodrome. Schizophrenia Bulletin, 33, 703 714.
63. Correll, C.U., Smith, C.W., Auther, A.M., McLaughlin, D., Shah, M., Foley, C., Olsen, R., Lencz, T., Kane, J.M. Cornblatt, B.A. (2008). Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. Journal of Child and Adolescent Psychopharmacology, 18, 475 490.
64. Cosi, C., Waget, A., Rollet, K., Tesori, V. Newman-Tancredi, A. (2005). Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: Role of 5-HT1A receptor activation. Brain Research, 1043, 32 41.
65. Desta, M., Tadesse, A., Gebre, N., Barci, B.M., Torrey, E.F. Knable, M.B. (2002). Controlled trial of hydroxychloroquine in schizophrenia. Journal of Clinical Psychopharmacology, 22, 507 510.
66. De Foubert, G., Carney, S.L., Robinson, C.S., Destexhe, E.J., Tomlinson, R., Hicks, C.A., Murray, T.K., Gaillard, J.P., Deville, C., Xhenseval, V., Thomas, C.E., O'Neill, M.J. Zetterstrom, T.S. (2004). Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience, 128, 597 604.
67. DeGrazia, D. (2001). Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophrenia Research, 51, 77 86.
68. De Koning, M.B., Bloemen, O.J., van Amelsvoort, T.A., Becker, H.E., Nieman, D.H., van der Gaag, M. Linszen, D.H. (2009). Early intervention in patients at ultra high risk of psychosis: Benefits and risks. Acta Psychiatrica Scandinavica, 119, 426 442.
69. De Witte, P., Littleton, J., Parot, P. Koob, G. (2005). Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs, 19, 517 537.
70. Do, K.Q., Trabesinger, A.H., Kirsten-Krüger, M., Lauer, C.J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P. Cuénod, M. (2000). Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience, 12, 3721 3728.
71. D'Sa, C. Duman, R.S. (2002). Antidepressants and neuroplasticity. Bipolar Disorders, 4, 183 194.
72. Duman, R.S., Nakagawa, S. Malberg, J. (2001). Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology, 25, 836 844.
73. Dursun, S.M. Deakin, J.F. (2001). Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. Journal of Psychopharmacology, 15, 297 301.
74. Dursun, S.M., McIntosh, D. Milliken, H. (1999). Clozapine plus lamotrigine in treatment-resistant schizophrenia. Archives of General Psychiatry, 56, 950.
75. Eastvold, A.D., Heaton, R.K. Cadenhead, K.S. (2007). Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophrenia Research, 93, 266 277.
76. Ehrenreich, H., Degner, D., Meller, J., Brines, M., Béhé, M., Hasselblatt, M., Woldt, H., Falkai, P., Knerlich, F., Jacob, S., von Ahsen, N., Maier, W., Brück, W., Rüther, E., Cerami, A., Becker, W. Sirén, A.L. (2004). Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Molecular Psychiatry, 9, 42 54.
77. Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., Erdag, S., Jahn, H., Degner, D., Ritzen, M., Mohr, A., Wagner, M., Schneider, U., Bohn, M., Huberm, M., Czernik, A., Pollmächer, T., Maier, W., Sirén, A.L., Klosterkötter, J., Falkai, P., Rüther, E., Aldenhoff, J.B. Krampe, H. (2007). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry, 12, 206 220.
78. Ehrenreich, H. Sirén, AL. (2001). Neuroprotection - what does it mean? What means do we have? European Archives of Psychiatry and Clinical Neuroscience, 251, 149 151.
79. Erickson, S.K., Schwarzkopf, S.B., Palumbo, D., Badgley-Fleeman, J., Smirnow, A.M. Light, G.A. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology, 28, 179 184.
80. Farber, N.B., Jiang, X.P., Heinkel, C. Nemmers, B. (2002). Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Molecular Psychiatry, 7, 726 733.
81. Fenton, W.S., Dickerson, F., Boronow, J., Hibbeln, J.R. Knable, M. (2001). A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry, 158, 2071 2074.
82. Fenton, W.S., Hibbeln, J. Knable, M. (2000). Essential fatty acids, lipid membraneabnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry, 47, 8 21.
83. Fornito, A., Yung, A.R., Wood, S.J., Phillips, L.J., Nelson, B., Cotton, S., Velakoulis, D., McGorry, P.D., Pantelis, C. Yücel, M. (2008). Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: An MRI study of ultra-high-risk individuals. Biological Psychiatry, 64, 758 765.
84. Francey, S.M., Jackson, H.J., Phillips, L.J., Wood, S.J., Yung, A.R. McGorry, P.D. (2005). Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophrenia Research, 79, 127 136.
85. Freudenreich, O., Herz, L., Deckersbach, T., Evins, A.E., Henderson, D.C., Cather, C. Goff, D.C. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 181, 358 363.
86. Frey, B.N., Andreazza, A.C., Kunz, M., Gomes, F.A., Quevedo, J., Salvador, M., Gonçalves, C.A. Kapczinski, F. (2007). Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 283 285.
87. Frey, B.N., Valvassori, S.S., Réus, G.Z., Martins, M.R., Petronilho, F.C., Bardini, K., Dal-Pizzol, F., Kapczinski, F. Quevedo, J. (2006). Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience, 31, 326 332.
88. Frommann, I., Brinkmeyer, J., Ruhrmann, S., Hack, E., Brockhaus-Dumke, A., Bechdolf, A., Wolwer, W., Klosterkötter, J., Maier, W. Wagner, M. (2008). Auditory P300 in individuals clinically at risk for psychosis. International Journal of Psychophysiology, 70, 192 205.
89. Fusar-Poli, P., Meneghelli, A., Valmaggia, L., Allen, P., Galvan, F., McGuire, P. Cocchi, A. (2009). Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. British Journal of Psychiatry, 194, 181 182.
90. Fusar-Poli, P., Valmaggia, L. McGuire, P. (2007). Can antidepressants prevent psychosis? Lancet, 370, 1746 1748.
91. Galvin, K.A. Oorschot, D.E. (1998). Postinjury magnesium sulfate treatment is not markedly neuroprotective for striatal medium spiny neurons after perinatal hypoxiaischemia in the rat. Pediatric Research, 44, 740 745.
92. Garner, B., Pariante, C.M., Wood, S.J., Velakoulis, D., Phillips, L., Soulsby, B., Brewer, W.J., Smith, D.J., Dazzan, P., Berger, G.E., Yung, A.R., van den Buuse, M., Murray, R., McGorry, P.D. Pantelis, C. (2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry, 58, 417 423.
93. Goff, D.C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A.C., Johnson, S.A. Lynch, G. (2001). A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of Clinical Psychopharmacology, 21, 484 487.
94. Gray, N.A., Zhou, R., Du, J., Moore, G.J. Manji, H.K. (2003). The use of mood stabilizers asplasticity enhancers in the treatment of neuropsychiatric disorders. Journal of Clinical Psychiatry, 64 (Suppl. 5 3 17.
95. Gross, G., Huber, G., Klosterkötter, J. Linz, M 1987). BSABS., Bonner Skala für die Beurteilung von Basissymptomen, Bonn Scale for the Assessment of Basic Symptoms, Berlin:Springer.
96. Gschwandtner, U., Pflueger, M.O., Semenin, V., Gaggiotti, M., Riecher-Rossler, A. Fuhr, P. (2009). EEG: A helpful tool in the prediction of psychosis. European Archives of Psychiatry and Clinical Neuroscience, 259, 257 262.
97. Gudlowski, Y., Ozgürdal, S., Witthaus, H., Gallinat, J., Hauser, M., Winter, C., Uhl, I., Heinz, A. Juckel, G. (2009). Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. Schizophrenia Research, 109, 141 147.
98. Hafner, H. AnderHeiden, W. (1999). The course of schizophrenia in the light of modern follow-up studies. The ABC and WHO studies. European Archives of Psychiatry and Clinical Neuroscience, 249 (Suppl. 4 14 26.
99. Hafner, H., Maurer, K. Loffler, W 1995). Onset and early course of schizophrenia. In H.G.W. Hafner (Ed Search for the causes of schizophrenia:Vol. 3 (pp. 43 66). Berlin:Springer-Verlag.
100. Hafner, H., Maurer, K., Loffler, W., anderHeiden, W., Munk-Jørgensen, P., Hambrecht, M. Else, S.O. (1998). The ABC Schizophrenia Study: A preliminary overview of the results. Social Psychiatry and Psychiatric Epidemiology, 33, 380 386.
101. Haller, S., Borgwardt, S.J., Schindler, C., Aston, J., Radue, E.W. Riecher-Rossler, A. (2009). Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study Radiology, 250, 212 221.
102. Haroun, N., Dunn, L., Haroun, A. Cadenhead, K.S. (2006). Risk and protection in prodromal schizophrenia: Ethical implications for clinical practice and future research. Schizophrenia Bulletin, 32, 166 178.
103. Harris, B.R., Gibson, D.A., Prendergast, M.A., Blanchard, J.A., Holley, R.C., Hart, S.R., Scotland, R.L., Foster, T.C., Pedigo, N.W. Littleton, J.M. (2003). The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcoholism: Clinical and Experimental Research, 27, 1724 1735.
104. Harsing, L.G Jr., Juranyi, Z., Gacsalyi, I., Tapolcsanyi, P., Czompa, A. Matyus, P. (2006). Glycine transporter type-1 and its inhibitors. Current Medicinal Chemistry, 13, 1017 1044.
105. Harvey, P.D., Rabinowitz, J., Eerdekens, M. Davidson, M. (2005). Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry, 162, 1888 1895.
106. Hashimoto, R., Hough, C., Nakazawa, T., Yamamoto, T. Chuang, D.M. (2002). Lithium protectionagainst glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Journal of Neurochemistry, 80, 589 597.
107. Hauser, M., Lautenschlager, M., Gudlowski, Y., Ozgürdal, S., Witthaus, H., Bechdolf, A., Bäuml, J., Heinz A. Juckel, G. (2009). Psychoeducation with patients at-risk for schizophrenia - an exploratory pilot study. Patient Education and Counseling, 76, 138 142.
108. Hauser, M., Pfennig, A., Ozgürdal, S., Heinz, A., Bauer, M. Juckel, G. (2007). Early recognition of bipolar disorder. European Psychiatry, 22, 92 98.
109. Hawkins, K.A., Addington, J., Keefe, R.S.E., Christensen, B., Perkins, D.O., Zipursky, R., Woods, S.W., Miller, T.J., Marquez, E., Breier, A. McGlashan, T.H. (2004). Neuropsychological status of subjects at high risk for a first episode of osychosis. Schizophrenia Research, 67, 115 122.
110. Hegarty, J.D., Baldessarini, R.J., Tohen, M., Waternaux, C. Oepen, G. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409 1416.
111. Heresco-Levy, U. (2006). Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia. Evidence Based Mental Health, 9, 48.
112. Heresco-Levy U. Javitt, D.C. (2004). Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis. Schizophrenia Research, 66, 89 96.
113. Heresco-Levy, U., Javitt, D.C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S. Ermilov, M. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry, 57, 577 585.
114. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G. Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry, 56, 29 36.
115. Heresco-Levy, U. Lerer, B 2009). http://clinicaltrial.gov/ct2/results? term=prodrome+AND+schizophrenia, accessed August 23, 2009.
116. Hoegyes, E., Nyakas, C., Kiliaan, A., Farkas, T., Penke, B. Luiten, PG. (2003). Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience, 119, 999 1012.
117. Horrobin, D.F., Jenkins, K., Bennett, C.N. Christie, W.W. (2002). Eicosapentaenoic acid andarachidonic acid: Collaboration and not antagonism is the key to biological understanding. Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 83 90.
118. Howes, O.D., Montgomery, A.J., Asselin, M.C., Murray, R.M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., McGuire, P.K. Grasby, P.M. (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry, 66, 13 20.
119. Huang, J.T-J., Leweke, F.M., Tsang, T.M., Koethe, D., Kranaster, L., Gerth, C.W., Gross, S., Schreiber, D., Ruhrmann, S., Schultze-Lutter, F., Klosterkötter, J., Holmes, E. Bahn, S. (2007). CSF metabolic and proteomic profiles in patients prodromal for psychosis. PloS ONE, 8, e756.
120. Hurlemann, R., Matusch, A., Kuhn, K.U., Berning, J., Elmenhorst, D., Winz, O., Kolsch, H., Zilles, K., Wagner, M., Maier, W. Bauer, A. (2008). 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology, 195, 579 590.
121. Javitt, DC. http://clinicaltrial.gov/ct2/results?term= prodrome+AND+schizophrenia, accessed August 23, 2009.
122. Johnson, S.A. Simmon, V.F. (2002). Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: A progress report. Journal of Molecular Neuroscience, 19, 197 200.
123. Kane, J.M., Krystal, J. Correll, C.U. (2003). Treatment models and designs for intervention research during the psychotic prodrome. Schizophrenia Bulletin, 29, 747 756.
124. Keefe, R.S., Perkins, D.O., Gu, H., Zipursky, RB., Christensen, B.K. Lieberman, J.A. (2006). A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia Research, 88, 26 35.
125. Keri, S. (2008). Psychosis prevention and early intervention in Hungary. Clinical Neuropsychiatry, 5, 295 302.
126. Keshavan, M.S., Berger, G., Zipursky, R.B., Wood, S.J. Pantelis, C. (2005). Neurobiology of early psychosis. British Journal of Psychiatry, 48 (Suppl. s8 s18.
127. Killestein, J., Kalkers, N.F. Polman, C.H. (2005). Glutamate inhibition in MS: The neuroprotective properties of riluzole. Journal of the Neurological Sciences, 233, 113 115.
128. Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N.Y. Beal M.F. (2004). Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 88, 576 582.
129. Klosterkötter, J., Hellmich, M., Steinmeyer, E.M. Schultze-Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58, 158 164.
130. Kodama, M., Fujioka, T. Duman, R.S 2004). Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry, 56, 570 580, Erratum in: Biological Psychiatry (2005), 57, 199.
131. Koethe, D., Kranaster, L., Hoyer, C., Gross, S., Neatby, M.A., Schultze-Lutter, F., Ruhrmann, S., Klosterkötter, J., Hellmich, M. Leweke, F.M. (2009). Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naive, and treated schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 259, 195 202.
132. Kolsch, H. Rao, M.L. (2002). Neuroprotective effects of estradiol-17beta: Implications for psychiatric disorders. Archives of Women's Mental Health, 5, 105 110.
133. Koutsouleris, N., Meisenzahl, E.M., Davatzikos, C., Bottlender, R., Frodl, T., Scheuerecker, J., Schmitt, G., Zetzsche, T., Decker, P., Reiser, M., Möller, H.J. Gaser, C. (2009). Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Archives of General Psychiatry, 66, 700 712.
134. Krebs, M., Leopold, K., Hinzpeter, A. Schaefer, M. (2006). Neuroprotective agents in schizophrenia and affective disorders. Expert Opinion in Pharmacotherapy, 7, 837 848.
135. Kristensen, K. Cadenhead, K.S. (2007). Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Research, 151, 151 154.
136. Kulkarni, J., de Castella, A., Fitzgerald, P.B., Gurvich, C.T., Bailey, M., Bartholomeusz, C. Burger, H. (2008). Estrogen in severe mental illness: A potential new treatment approach. Archives of General Psychiatry, 65, 955 960.
137. Kulkarni, J., de Castella, A., Smith, D., Taffe, J., Keks, N. Copolov, D. (1996). A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research, 20, 247 252.
138. Kulkarni, J., Riedel, A., de Castella, A.R., Fitzgerald, P.B., Rolfe, T.J., Taffe J. Burger, H. (2001). Estrogen - a potential treatment for schizophrenia. Schizophrenia Research, 48, 137 144.
139. Kulkarni, J., Riedel, A., de Castella, A.R., Fitzgerald, P.B., Rolfe, T.J., Taffe, J. Burger, H. (2002). A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Archives of Women's Mental Health, 5, 99 104.
140. Kumari, V., Aasen, I., ffytche, D., Williams, S.C. Sharma, T. (2006). Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study. Neuroimage, 29, 545 556.
141. Lappin, J.M., Dazzan, P., Morgan, K., Morgan, C., Chitnis, X., Suckling, J., Fearon, P., Jones, P.B., Leff, J., Murray, R.M. McGuire, P.K. (2007). Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. British Journal of Psychiatry, 51 (Suppl. s123 s127.
142. Lauritzen, I., Blondeau, N., Heurteaux, C., Widmann, C., Romey, G. Lazdunski, M. (2000). Polyunsaturated fatty acids are potent neuroprotectors. EMBO Journal, 19, 1784 1793.
143. Lavoie, S., Murray, M.M., Deppen, P., Knyazeva, M.G., Berk, M., Boulat, O., Bovet, P., Bush, A.I., Conus, P., Copolov, D., Fornari, E., Meuli, R., Solida, A., Vianin, P., Cuénod, M., Buclin, T. Do, K.Q. (2008). Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 33, 2187 2199.
144. Lencz, T., Smith, C.W., Auther, A., Correll, C.U. Cornblatt, B. (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 68, 37 48.
145. Lencz, T., Smith, C.W., McLaughlin, D., Auther, A., Nakayama, E., Hovey, L. Cornblatt, B.A. (2006). Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biological Psychiatry, 59, 863 871.
146. Lewis, D.A. Gonzalez-Burgos, G. (2006). Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine, 12, 1016 1022.
147. Li, X.M., Chlan-Fourney, J., Juorio, A.V., Bennett, V.L., Shrikhande, S. Bowen, R.C. (2000). Antidepressants upregulate messenger RNA levels of the neuroprotective enzyme superoxide dismutase (SOD1). Journal of Psychiatry and Neuroscience, 25, 43 47.
148. Li, X.M., Chlan-Fourney, J., Juorio, A.V., Bennett, V.L., Shrikhande, S., Keegan, D.L., Qi, J. Boulton, A.A. (1999). Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. Journal of Neuroscience Research, 56, 72 75.
149. Libien, J., Sacktor, T.C. Kass, I.S. (2005). Magnesium blocks the loss of protein kinase C., leads to a transient translocation of PKC(alpha) and PKC(epsilon), and improves recovery after anoxia in rat hippocampal slices. Brain Research. Molecular Brain Research, 136, 104 111.
150. Lieberman, J.A., Tollefson, G.D., Charles, C., Zipursky, R., Sharma, T., Kahn, R.S., Keefe, R.S., Green, A.I., Gur, R.E., McEvoy, J., Perkins, D., Hamer, R.M., Gu, H. Tohen, M HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361 370.
151. Lonergan, P.E., Martin, D.S., Horrobin, D.F. Lynch, M.A. (2002). Neuroprotective effect ofeicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. Journal of Biological Chemistry, 277, 20804 20811.
152. Luoma, S., Hakko, H., Ollinen, T., Järvelin, MR. Lindeman, S. (2008). Association between age at onset and clinical features of schizophrenia: The Northern Finland 1966 birth cohort study. European Psychiatry, 23, 331 335.
153. Maes, M., Bocchio Chiavetto, L., Bignotti, S., Battisa Tura, G.J., Pioli, R., Boin, F., Kenis, G., Bosmans, E., de Jongh, R. Altamura, C.A. (2002). Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophrenia Research, 54, 281 291.
154. Maes, M., Bocchio Chiavetto, L., Bignotti, S., Battisa Tura, G., Pioli, R., Boin, F., Kenis, G., Bosmans, E., de Jongh, R., Lin, A., Racagni, G. Altamura, C.A. (2000). Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology, 10, 119 124.
155. Malberg, J.E., Eisch, A.J., Nestler, E.J. Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience, 20, 9104 9110.
156. Manji, H.K., McNamara, R., Chen, G. Lenox, R.H. (1999). Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manic-depressive illness. Australia and New Zealand Journal of Psychiatry, 33 (Suppl. s65 s83.
157. Manji, H.K., Moore, G.J. Chen, G. (2000). Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness. Journal of Clinical Psychiatry, 61 (Suppl. 9 82 96.
158. Marenco, S., Egan, M.F., Goldberg, T.E., Knable, M.B., McClure, R.K., Winterer, G. Weinberger, D.R. (2002). Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series. Schizophrenia Research, 57, 221 226.
159. Marenco, S. Weinberger, D.R. (2000). The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Development and Psychopathology, 12, 501 527.
160. Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P. Croudace, T. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry, 62, 975 983.
161. Martin, D.S., Lonergan, P.E., Boland, B., Fogarty, M.P., Brady, M., Horrobin, D.F., Campbell, V.A. Lynch, M.A. (2002a). Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. Journal of Biological Chemistry, 277, 34239 34246.
162. Martin, D.S., Spencer, P., Horrobin, D.F. Lynch, M.A. (2002b). Long-term potentiation in aged rats is restored when the age-related decrease in polyunsaturated fatty acid concentration is reversed. Prostaglandins, Leukotrienes and Essential Fatty Acids, 67, 121 130.
163. McFarlane, W.R., Dixon, L., Lukens, E. Lucksted, A. (2003). Family psychoeducation and schizophrenia: A review of the literature. Journal of Marital and Family Therapy, 29, 223 245.
164. McGlashan, T.H. (2001). Psychosis treatment prior to psychosis onset: Ethical issues. Schizophrenia Research, 51, 47 54.
165. McGlashan, T.H. Johannessen, J.O. (1996). Early detection and intervention with schizophrenia: Rationale. Schizophrenia Bulletin, 22, 201 222.
166. McGlashan, T.H., Zipursky, R.B., Perkins, D., Addington, J., Miller, T.J., Woods, S.W., Hawkins, K.A., Hoffman, R., Lindborg, S., Tohen, M. Breier, A. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research, 61, 7 18.
167. McGlashan, T.H., Zipursky, R.B., Perkins, D., Addington, J., Miller, T., Woods, S.W., Hawkins, K.A., Hoffman, R.E., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M. Breier, A. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790 799.
168. McGorry, P.D. (1998). 'A stitch in time'... the scope for preventive strategies in early psychosis. European Archives of Psychiatry and Clinical Neuroscience, 248, 22 31.
169. McGorry, P.D., Hickie, I.B., Yung, A.R., Pantelis, C. Jackson, H.J. (2006). Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. Australia and New Zealand Journal of Psychiatry, 40, 616 622.
170. McGorry, P.D., Nelson, B., Amminger, G.P., Bechdolf, A., Francey, S.M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., Nordentoft, M., Hickie, I., McGuire, P., Berk, M., Chen, E.Y., Keshavan, M.S. Yung, AR 2009). Intervention in individuals at ultra high risk for psychosis: A review and future directions. Journal of Clinical Psychiatry [Epub ahead of print].
171. McGorry, P.D., Yung, A. Phillips, L. (2001). Ethics and early intervention in psychosis: Keeping up the pace and staying in step. Schizophrenia Research, 51, 17 29.
172. McGorry, P.D., Yung, A.R. Phillips, L.J. (2003). The 'close-in' or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophrenia Bulletin, 29, 771 790.
173. McGorry, P.D., Yung, A.R., Phillips, L.J., Yuen, H.P., Francey, S., Cosgrave, E.M., Germano, D., Bravin, J., McDonald, T., Blair, A., Adlard, S. Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921 928.
174. Meares, A. (1959). The diagnosis of prepsychotic schizophrenia. Lancet, 10, 55 58.
175. Meisenzahl, E.M., Koutsouleris, N., Gaser, C., Bottlender, R., Schmitt, G.J., McGuire, P., Decker, P., Burgermeister, B., Born, C., Reiser, M. Möller, H.J. (2008). Structural brain alterations in subjects at high-risk of psychosis: A voxel-based morphometric study. Schizophrenia Research, 102, 150 162.
176. Miguel-Hidalgo, J.J. Rajkowska, G. (2002). Morphological brain changes in depression: Can antidepressants reverse them? CNS Drugs, 16, 361 372.
177. Miller, T.J., McGlashan, T.H., Rosen, J.L., Cadenhead, K., Cannon, T., Ventura, J., McFarlane, W., Perkins, D.O., Pearlson, G.D. Woods, SW 2003). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin, 29, 703 715. Erratum in: Schizophrenia Bulletin (2004), 30, following 217.
178. Miller, T.J., McGlashan, T.H., Rosen, J.L., Somjee, L., Markovich, P.J., Stein, K. Woods, S.W. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry, 159, 863 865.
179. Miller, T.J., McGlashan, T.H., Woods, S.W., Stein, K., Driesen, N., Corcoran, C.M., Hoffman, R. Davidson, L. (1999). Symptom assessment in schizophrenic prodromal states. Psychiatric Quarterly, 70, 273 287.
180. Moore, G.J., Bebchuk, J.M., Hasanat, K., Chen, G., Seraji-Bozorgzad, N., Wilds, I.B., Faulk, M.W., Koch, S., Glitz, D.A., Jolkovsky, L. Manji, H.K 2000). Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects? Biological Psychiatry, 48, 1 8, Erratum in: Lancet (2000), 356, 2104: Menji HK [corrected to Manji HK].
181. Morey, R.A., Inan, S., Mitchell, T.V., Perkins, D.O., Lieberman, J.A. Belger, A. (2005). Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry, 62, 254 262.
182. Morrison, A.P., French, P., Parker, S., Roberts, M., Stevens, H., Bentall, R.P. Lewis, S.W. (2007). Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin, 33, 682 687.
183. Morrison, A.P., French, P., Walford, L., Lewis, S.W., Kilcommons, A., Green, J., Parker, S. Bentall, R.P. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. British Journal of Psychiatry, 185, 291 297.
184. Mrazek, P.J. Haggerty, R.J. (Eds 1994). Reducing risk for mental disorders: Frontiers for preventive intervention research. Washington, DC:National Academic Press.
185. Muller, N., Riedel, M., Scheppach, C., Brandstatter, B., SokulLu, S., Krampe, K., Ulmschneider, M., Engel, R.R., Moller, H.J. Schwarz, M.J. (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry, 159, 1029 1034.
186. Myles-Worsley, M., Ord, L.M., Ngiralmau, H., Weaver, S., Blailes, F. Faraone, S.V. (2007). The Palau Early Psychosis Study: Neurocognitive functioning in high-risk adolescents. Schizophrenia Research, 89, 299 307.
187. Nieman, D., Becker, H., van de Fliert, R., Plat, N., Bour, L., Koelman, H., Klaassen, M., Dingemans, P., Niessen, M. Linszen, D. (2007). Antisaccade task performance in patients at ultra high risk for developing psychosis. Schizophrenia Research, 95, 54 60.
188. Niendam, T.A., Bearden, C.E., Johnson, J.K., McKinley, M., Loewy, R., O'Brien, M., Nuechterlein, K.H., Green, M.F. Cannon, T.D. (2006). Neurocognitive performance and functional disability in the psychosis prodrome. Schizophrenia Research, 84, 100 111.
189. Niendam, T.A., Bearden, C.E., Zinberg, J., Johnson, J.K., O'Brien, M. Cannon, T.D. (2007). The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophrenia Bulletin, 33, 772 781.
190. Niendam, T.A., Jalbrzikowski, M. Bearden, C.E 2009). Exploring predictors of outcome in the psychosis prodrome: Implications for early identification and intervention. Neuropsychology Review [Epub ahead of print].
191. Nonaka, S., Katsube, N. Chuang, D.M. (1998). Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. Journal of Pharmacology and Experimental Therapeutics, 286, 539 547.
192. Norman, R.M. Malla, A.K. (2001). Duration of untreated psychosis: A critical examination of the concept and its importance. Psychological Medicine, 31, 381 400.
193. O'Brien, M.P., Zinberg, J.L., Ho, L., Rudd, A., Kopelowicz, A., Daley, M., Bearden, C.E. Cannon, TD. (2009). Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: A longitudinal study. Schizophrenia Research, 107, 198 205.
194. Okamura, N., Hashimoto, K., Kanahara, N., Shimizu, E., Kumakiri, C., Komatsu, N. Iyo, M. (2003). Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. European Journal ofPharmacology, 461, 93 98.
195. Olsen, K.A. Rosenbaum, B. (2006). Prospective investigations of the prodromal state of schizophrenia: Review of studies. Acta Psychiatrica Scandinavica, 113, 247 272.
196. Olsen, K.A. Rosenbaum, B. (2006). Prospective investigations of the prodromal state of schizophrenia: Assessment instruments. Acta Psychiatrica Scandinavica, 113, 273 282.
197. Overall, J.E. Gorham, D.R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799 812.
198. Ozgürdal, S., Gudlowski, Y., Witthaus, H., Kawohl, W., Uhl, I., Hauser, M., Gorynia, I., Gallinat, J., Heinze, M., Heinz, A. Juckel, G. (2008). Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia. Schizophrenia Research, 105, 272 278.
199. Ozgürdal, S., Littmann, E., Hauser, M., von Reventlow, H., Gudlowski, Y., Witthaus, H., Heinz, A. Juckel, G. (2009a). Neurocognitive performances in participants of at-risk mental state for schizophrenia and in first-episode patients. Journal of Clinical and Experimental Neuropsychology, 31, 392 401.
200. Ozgürdal, S., van Haren, E., Hauser, M., Ströhle, A., Bauer, M., Assion, H.J. Juckel, G. (2009b). Early mood swings as symptoms of the bipolar prodrome: Preliminary results of a retrospective analysis. Psychopathology, 42, 337 342.
201. Padma, M. Das, U.N. (1999). Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation in macrophage tumor (AK-5) cells in vitro. Prostaglandins, Leukotrienes and Essential Fatty Acids, 60, 55 63.
202. Pantelis, C., Velakoulis, D., Wood, S.J., Yücel, M., Yung, A.R., Phillips, L.J., Sun, D.Q. McGorry, P.D. (2007). Neuroimaging and emerging psychotic disorders: The Melbourne ultra-high risk studies. International Review of Psychiatry, 19, 371 381.
203. Pantelis, C., Yücel, M., Wood, S.J., McGorry, P.D. Velakoulis, D. (2003). Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Australia and New Zealand Journal of Psychiatry, 37, 399 406.
204. Pantelis, C., Yücel M., Wood, S.J., Velakoulis, D., Sun, D., Berger, G., Stuart, GW., Yung, A., Phillips, L. McGorry, P.D. (2005). Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin, 31, 672 696.
205. Parikh, V., Khan, M.M. Mahadik, S.P. (2003). Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 37, 43 51.
206. Peet, M., Brind, J., Ramchand, C.N., Shah, S. Vankar, G.K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 49, 243 251.
207. Perkins, D.O., Gu, H., Boteva, K. Lieberman, J.A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. American Journal of Psychiatry, 162, 1785 1804.
208. Pflueger, M.O., Gschwandtner, U., Stieglitz, R.D. Riecher-Rössler, A. (2007). Neuropsychological deficits in individuals with an at risk mental state for psychosis - working memory as a potential trait marker. Schizophrenia Research, 97, 14 24.
209. Phillips, L.J., Curry, C., Yung, A.R., Yuen, H.P., Adlard, S. McGorry, P.D. (2002b). Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Australia and New Zealand Journal of Psychiatry, 36, 800 806.
210. Phillips, L.J., McGorry, P.D., Yuen, H.P., Ward, J., Donovan, K., Kelly, D., Francey, S.M. Yung, A.R. (2007). Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research, 96, 25 33.
211. Phillips, L.J., Velakoulis, D., Pantelis, C., Wood, S., Yuen, H.P., Yung, A.R., Desmond, P., Brewer, W. McGorry, P.D. (2002a). Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophrenia Research, 58, 145 158.
212. Phillips, L.J., Yung, A.R. McGorry, P.D. (2000). Identification of young people at risk of psychosis: Validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Australia and New Zealand Journal of Psychiatry, 34 (Suppl. s164 s169.
213. Platz, C., Umbricht, D.S., Cattapan-Ludewig, K., Dvorsky, D., Arbach, D., Brenner, H.D. Simon, A.E. (2006). Help-seeking pathways in early psychosis. Social Psychiatry and Psychiatric Epidemiology, 41, 967 974.
214. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R. Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biological Psychiatry, 63, 801 818.
215. Pukrop, R., Ruhrmann, S., Schultze-Lutter, F., Bechdolf, A., Brockhaus-Dumke, A. Klosterkötter, J. (2007). Neurocognitive indicators for a conversion to psychosis: Comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophrenia Research, 92, 116 125.
216. Puri, B.K., Bydder, G.M., Counsell, S.J., Corridan, B.J., Richardson, A.J., Hajnal, J.V., Appel, C., Mckee, H.M., Vaddadi, K.S. Horrobin, D.F. (2002). MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport, 13, 123 126.
217. Puri, B.K. Richardson, A.J. (1998). Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry, 55, 188 189.
218. Qing, H., Xu, H., Wei, Z., Gibson, K. Li, X.M. (2003). The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. European Journal of Neuroscience, 17, 1563 1570.
219. Quednow, B.B., Frommann, I., Berning, J., Kühn, K.U., Maier, W. Wagner, M. (2008). Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biological Psychiatry, 64, 766 773.
220. Ranjekar, P.K., Hinge, A., Hegde, M.V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U.V., Debsikdar, V.B. Mahadik, S.P. (2003). Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research, 121, 109 122.
221. Rantamaki, T., Hendolin, P., Kankaanpaa, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M.V., Männistö, P.T. Castrén, E. (2007). Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology, 32, 2152 2162.
222. Robinson, D.G., Woerner, M.G., McMeniman, M., Mendelowitz, A. Bilder, R.M. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 473 479.
223. Rosen, J.L., Miller, T.J., D'Andrea, J.T., McGlashan, T.H. Woods, S.W. (2006). Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophrenia Research, 85, 124 131.
224. Ruhrmann, S 2008). Presented at the SIRS Meeting, Venice, June.
225. Ruhrmann, S., Bechdolf, A., Kühn, K.U., Wagner, M., Schultze-Lutter, F., Janssen, B., Maurer, K., Häfner, H., Gaebel, W., Möller, H.J., Maier, W. Klosterkötter, J LIPS study group (2007). Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry, 51 (Suppl s88 sS95.
226. Ruhrmann, S., Paruch, J., Bechdolf, A., Pukrop, R., Wagner, M., Berning, J., Schultze-Lutter, F., Janssen, B., Gaebel, W., Moller, H.J., Maier, W. Klosterkötter, J. (2008). Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatrica Scandinavica, 117, 357 368.
227. Ruhrmann, S., Schultze-Lutter, F. Klosterkötter, J. (2003). Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 36 (Suppl. 3 s162 s167.
228. Ruhrmann, S., Schultze-Lutter, F. Klosterkötter, J. (2009). Intervention in the at-risk state to prevent transition to psychosis. Current Opinion in Psychiatry, 22, 177 183.
229. Ruhrmann, S., Schultze-Lutter, F., Salokangas, R.K.R., Heinimaa, M., Linszen, D., Dingemans, P.M., Birchwood, M., Patterson, P., Juckel, G., Heinz, A., Morrison, A., Lewis, S., Graf von Reventlow, H. Klosterkötter, J in press). Prediction of psychosis in adolescents and young adults at high risk: Results from the prospective European Prediction of Psychosis Study (EPOS). Archives of General Psychiatry.
230. Rummel, C., Kissling, W. Leucht, S. (2005). Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. Schizophrenia Research, 80, 85 97.
231. Saatman, K.E., Bareyre, F.M., Grady, M.S. McIntosh, T.K. (2001). Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. Journal of Neuropathology and Experimental Neurology, 60, 183 194.
232. Sameshima, H. Ikenoue, T. (2001). Long-term magnesium sulfate treatment as protection against hypoxic-ischemic brain injury in seven-day-old rats. American Journal of Obstetrics and Gynecology, 184, 185 190.
233. Sanchez, V., Camarero, J., Esteban, B., Peter, M.J., Green, A.R. Colado, M.I. (2001). The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA. ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. British Journal of Pharmacology, 134, 46 57.
234. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., Belzung, C. Hen, R. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301, 805 809.
235. Salzman, SK., Kelly, G., Chavin, J., Wang, L., Puniak, M.A., Agresta, C.A. Azim, S. (1994). Characterization of mianserin neuroprotection in experimental spinal trauma: DoseRoute response and late treatment. Journal of Pharmacology and Experimental Therapeutics, 269, 322 328.
236. Saxena, K., Howe, M., Simeonova, D., Steiner, H. Chang, K. (2006). Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 16, 252 259.
237. Schaffner, K.F. McGorry, P.D. (2001). Preventing severe mental illnesses - new prospects and ethical challenges. Schizophrenia Research, 51, 3 15.
238. Schall, U., Atkinson, R., Hunt, S., Inkpen, R., Stojanov, W., Hembold, K., Halpin, S., Carr, V. Michie, P. (2008). Mismatch negativity and prepulse inhibition in the prodrome. Schizophrenia Research, 102 (Suppl. 2 22 23.
239. Schimmelmann, B.G., Huber, C.G., Lambert, M., Cotton, S., McGorry, P.D. Conus, P. (2008). Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. Journal of Psychiatric Research, 42, 982 990.
240. Schultze-Lutter, F. (2009). Subjective symptoms of schizophrenia in research and the clinic: The basic symptom concept. Schizophrenia Bulletin, 35, 5 8.
241. Schultze-Lutter, F., Klosterkötter, J., Picker, H., Steinmeyer, E-M. Ruhrmann, S. (2007b). Predicting First-Episode Psychosis by Basic Symptom Criteria. Clinical Neuropsychiatry, 4, 11 22.
242. Schultze-Lutter, F., Picker, H., Ruhrmann, S. Klosterkötter, J. (2008). Das Kölner Früh-Erkennungs- & Therapie-Zentrum für psychische Krisen (FETZ): Evaluation der Inanspruchnahme. Medizinische Klinik, 103, 81 89.
243. Schultze-Lutter, F., Ruhrmann, S., Hoyer, C., Klosterkötter, J. Leweke, FM. (2007a). The initial prodrome of schizophrenia: Different duration, different underlying deficits? Comprehensive Psychiatry, 48, 479 488.
244. Schultze-Lutter, F., Ruhrmann, S. Klosterkötter, J 2006). Can schizophrenia be predicted phenomenologically? In J.O. Johannessen, B. Martindale J. Cullberg (Eds Evolving psychosis, different stages, different treatments (pp. 104 123). London:Routledge.
245. Schultze-Lutter, F., Ruhrmann, S., Picker, H., von Reventlow, H.G., Brockhaus-Dumke, A. Klosterkötter, J. (2007c). Basic symptoms in early psychotic and depressive disorders. British Journal of Psychiatry, 51 (Suppl. s31 s37.
246. Serafeim, A., Holder, M.J., Grafton, G., Chamba, A., Drayson, M.T., Luong, QT., Bunce, C.M., Gregory, C.D., Barnes, N.M. Gordon, J. (2003). Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood, 101, 3212 3219.
247. Seung Kim, H.F., Weeber, E.J., Sweatt, J.D., Stoll, A.L. Marangell, L.B. (2001). Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Molecular Psychiatry, 6, 246 248.
248. Sevy, S., Rosenthal, M.H., Alvir, J., Meyer, S., Visweswaraiah, H., Gunduz-Bruce, H. Schooler, N.R. (2005). Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Journal of Clinical Psychiatry, 66, 839 843.
249. Shao, L., Young, L.T. Wang, J.F. (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biological Psychiatry, 58, 879 884.
250. Shim, G., Kang, D.H., Chung, Y.S., Yoo, S.Y., Shin, N.Y. Kwon, J.S. (2008). Social functioning deficits in young people at risk for schizophrenia. Australia and New Zealand Journal of Psychiatry, 42, 678 685.
251. Shin, K.S., Kim, J.S., Kang, D.H., Koh, Y., Choi, J.S., O'Donnell, B.F., Chung, C.K. Kwon, J.S. (2009). Pre-attentive auditory processing in ultra-high-risk for schizophrenia with magnetoencephalography. Biological Psychiatry, 65, 1071 1078.
252. Shoham, S., Mazeh, H., Javitt, D.C. Heresco-Levy, U. (2004). Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Research, 1004, 142 147.
253. Simon, A.E., Cattapan-Ludewig, K., Zmilacher, S., Arbach, D., Gruber, K., Dvorsky, D.N., Roth, B., Isler, E., Zimmer, A. Umbricht, D. (2007). Cognitive functioning in the schizophrenia prodrome. Schizophrenia Bulletin, 33, 761 771.
254. Simon, A.E., Lauber, C., Ludewig, K., Braun-Scharm, H. Umbricht, D.S Swiss Early Psychosis Project (2005). General practitioners and schizophrenia: Results from a Swiss survey. British Journal of Psychiatry, 187, 274 281.
255. Simon, A.E., Lester, H., Tait, L., Stip, E., Roy, P., Conrad, G., Hunt, J., Epstein, I., Larsen, T.K., Amminger, P., Holub, D., Wenigová, B., Turner, M., Berger, G.E., O'Donnell, C. Umbricht, D. (2009). The International Study on General Practitioners and Early Psychosis (IGPS). Schizophrenia Research, 108, 182 190.
256. Simon, A.E., Dvorsky, D.N., Boesch, J., Roth, B., Isler, E., Schueler, P., Petralli, C. Umbricht, D. (2006). Defining subjects at risk for psychosis: A comparison of two approaches. Schizophrenia Research, 81, 83 90.
257. Siris, S.G., Bermanzohn, P.C., Mason, S.E. Shuwall, M.A. (1994). Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Archives of General Psychiatry, 51, 109 115.
258. Skeate, A., Patterson, P. BirchWood, M. (2004). Transition to psychosis in a high-risk sample: The experience of ED:IT., Birmingham, UK. Schizophrenia Research, 70 (Suppl. 1 s44.
259. Smith, CW., Park, S. Cornblatt, B. (2006). Spatial working memory deficits in adolescents at clinical high risk for schizophrenia. Schizophrenia Research, 81, 211 215.
260. Stone, J.M., Day, F., Tsagaraki, H., Valli, I., McLean, M.A., Lythgoe, D.J., O'Gorman, R.L., Barker, G.J. McGuire, P.K on Behalf of OASIS 2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume. Biological Psychiatry [Epub ahead of print].
261. Sun, D., Phillips, L., Velakoulis, D., Yung, A., McGorry, P.D., Wood, S.J., van Erp, T.G., Thompson, P.M., Toga, A.W., Cannon, T.D. Pantelis, C. (2009). Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophrenia Research, 108, 85 92.
262. Takahashi, T., Wood, S.J., Yung, A.R., Soulsby, B., McGorry, P.D., Suzuki, M., Kawasaki, Y., Phillips, L.J., Velakoulis, D. Pantelis, C. (2009). Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Archives of General Psychiatry, 66, 366 376.
263. Takahashi, T., Yücel, M., Yung, A.R., Wood, S.J., Phillips, L.J., Berger, G.E., Ang, A., Soulsby, B., McGorry, P.D., Suzuki, M., Velakoulis, D. Pantelis, C. (2008b). Adhesio interthalamica in individuals at high-risk for developing psychosis and patients with psychotic disorders. Progress in Neuro-Psychopharmacology and Biolological Psychiatry, 32, 1708 1714.
264. Takahashi, T., Yung, A.R., Yücel, M., Wood, S.J., Phillips, L.J., Harding, I.H., Soulsby, B., McGorry, P.D., Suzuki, M., Velakoulis, D. Pantelis, C. (2008a). Prevalence of large cavum septi pellucidi in ultra high-risk individuals and patients with psychotic disorders. Schizophrenia Research, 105, 236 244.
265. Tandon, R., Nasrallah, H.A. Keshavan, M.S. (2009). Schizophrenia, 'just the facts' 4. Clinical features and conceptualization. Schizophrenia Research, 110, 1 23.
266. Thomas, P., Alptekin, K., Gheorghe, M., Mauri, M., Olivares, J.M. Riedel, M. (2009). Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs, 23, 193 212.
267. Thompson, K.N., Berger, G., Phillips, L.J., Komesaroff, P., Purcell, R. McGorry, P.D. (2007). HPA axis functioning associated with transition to psychosis: Combined DEXCRH test. Journal of Psychiatric Research, 41, 446 450.
268. Tiihonen, J., Halonen, P., Wahlbeck, K., Repo-Tiihonen, E., Hyvärinen, S., Eronen, M., Putkonen, H., Takala, P., Mehtonen, O.P., Puck, M., Oksanen, J., Koskelainen, P., Joffe, G., Aer, J., Hallikainen, T., Ryynänen, O.P. Tupala, E. (2005). Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychiatry, 66, 1012 1015.
269. Tsai, G.E., Yang, P., Chang, Y.C. Chong, M.Y. (2006). D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 59, 230 234.
270. Velakoulis, D., Wood, S.J., Wong, M.T., McGorry, P.D., Yung, A., Phillips, L., Smith, D., Brewer, W., Proffitt, T., Desmond, P. Pantelis, C. (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry, 63, 139 149.
271. Velthorst, E., Nieman, D.H., Becker, H.E., van de Fliert, R., Dingemans, P.M., Klaassen, R., de Haan, L., van Amelsvoort, T. Linszen, D.H. (2009). Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophrenia Research, 109, 60 65.
272. Vinogradov, S. http://clinicaltrial.gov/ct2/results?term= prodrome+AND+schizophrenia, accessed August 23, 2009.
273. Volz, A., Khorsand, V., Gillies, D. Leucht, S. (2007). Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews, 24, CD006391.
274. Wainwright, P.E., Jalali, E., L.M., Bell, R. Cvitkovic, S. (1999). An imbalance of dietary essential fatty acids retards behavioral development in mice. Physiology and Behavior, 66, 833 839.
275. Wakade, C.G., Mahadik, S.P., Waller, J.L. Chiu, F.C. (2002). Atypical neuroleptics stimulate neurogenesis in adult rat brain. Journal of Neuroscience Research, 69, 72 79.
276. Walker, E.F. (1994). Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophrenia Bulletin, 20, 453 480.
277. Walker, E.F., Diforio, D. Baum, K. (1999). Developmental neuropathology and the precursors of schizophrenia. Acta Psychiatrica Scandinavica, 395 (Suppl. s12 s19.
278. Walker, E., Savoie, T. Davis, D. (1994). Neuromotor precursors of schizophrenia. Schizophrenia Bulletin, 20, 441 451.
279. Walterfang, M., Yung, A., Wood, A.G., Reutens, D.C., Phillips, L., Wood, S.J., Chen, J., Velakoulis, D., McGorry, P.D. Pantelis, C. (2008). Corpus callosum shape alterations in individuals prior to the onset of psychosis. Schizophrenia Research, 103, 1 10.
280. Wang, J.F., Azzam, J.E. Young, L.T. (2003). Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience, 116, 485 489.
281. Wang, J.F., Bown, C. Young, L.T. (1999). Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Molecular Pharmacology, 55, 521 527.
282. Wang, H.D., Dunnavant, F.D., Jarman, T. Deutch, A.Y. (2004). Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology, 29, 1230 1238.
283. Wei, Z., Bai O., Richardson, J.S., Mousseau, D.D. Li, X.M. (2003). Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. Journal of Neuroscience Research, 73, 364 368.
284. Whitford, T.J., Grieve, S.M., Farrow, T.F., Gomes, L., Brennan, J., Harris, A.W., Gordon, E. Williams, L.M. (2006). Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: A tensor-based morphometry study. Neuroimage, 32, 511 519.
285. Witthaus, H., Brüne, M., Kaufmann, C., Bohner, G., Ozgürdal, S., Gudlowski, Y., Heinz, A., Klingebiel, R. Juckel, G. (2008). White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophrenia Research, 102, 141 149.
286. Wood, S.J., Berger, G., Velakoulis, D., Phillips, L.J., McGorry, P.D., Yung, A.R., Desmond, P. Pantelis, C. (2003). Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophrenia Bulletin, 29, 831 843.
287. Wood, S.J., Brewer, W.J., Koutsouradis, P., Phillips, L.J., Francey, S.M., Proffitt, T.M., Yung, A.R., Jackson, H.J., McGorry, P.D. Pantelis, C. (2007). Cognitive decline following psychosis onset: Data from the PACE clinic. British Journal of Psychiatry, 51 (Suppl. s52 s7.
288. Wood, S.J., Yücel, M., Velakoulis, D., Phillips, L.J., Yung, A.R., Brewer, W., McGorry, P.D. Pantelis, C. (2005). Hippocampal and anterior cingulate morphology in subjects at ultra-high-risk for psychosis: The role of family history of psychotic illness. Schizophrenia Research, 75, 295 301.
289. Woods, S.W. http://clinicaltrial.gov/ct2/results?term= prodrome+AND+schizophrenia, accessed August 23, 2009.
290. Woods, S.W., Breier, A., Zipursky, R.B., Perkins, D.O., Addington, J., Miller, T.J., Hawkins, K.A., Marquez, E., Lindborg, S.R., Tohen, M. McGlashan, T.H 2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453 464. Erratum in: Biological Psychiatry (2003), 15, 54, 497.
291. Woods, S.W., Tully, E.M., Walsh, B.C., Hawkins, K.A., Callahan, J.L., Cohen, S.J., Mathalon, D.H., Miller, T.J. McGlashan, T.H. (2007). Aripiprazole in the treatment of the psychosis prodrome: An open-label pilot study. British Journal of Psychiatry, 51 (Suppl. s96 s101.
292. Wyatt, R. (1991). Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophrenia Research, 5, 201 202.
293. Wyatt, R. Henter, I. (2001). Rationale for the study of early intervention. Schizophrenia Research, 51, 69 76.
294. Xu, H., Qing, H., Lu, W., Keegan, D., Richardson, J.S., Chlan-Fourney, J. Li, X.M. (2002). Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neuroscience Letters, 321, 65 68.
295. Yang, Y., Li, Q., Ahmad, F. Shuaib, A. (2000). Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neuroscience Letters, 285, 119 122.
296. Yehuda, S., Carasso, R.L. Mostofsky, D.I. (1994). Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. European Journal of Pharmacology, 254, 193 198.
297. Yuan, P.X., Huang, L.D., Jiang, Y.M., Gutkind, J.S., Manji, H.K. Chen, G. (2001). The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. Journal of Biological Chemistry, 276, 31674 31683.
298. Yun, Y., Phillips, L.J., Cotton, S., Yung, A.R., Francey, S.M., Yuen, H.P. McGorry, P.D. (2005). Obstetric complications and transition to psychosis in an 'ultra' high risk sample. Australia and New Zealand Journal of Psychiatry, 39, 460 466.
299. Yung, A 2008). Presented at the SIRS Meeting, Venice, June.
300. Yung, A.R., Buckby, J.A., Cosgrave, E.M., Killackey, E.J., Baker, K., Cotton, S.M. McGorry, P.D. (2007b). Association between psychotic experiences and depression in a clinical sample over 6 months. Schizophrenia Research, 91, 246 253.
301. Yung, A.R., Killackey, E., Hetrick, S.E., Parker, A.G., Schultze-Lutter, F., Klosterkötter, J., Purcell, R. McGorry, P.D. (2007a). The prevention of schizophrenia. International Review of Psychiatry, 19, 633 646.
302. Yung, A.R. McGorry, P.D. (1996a). The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophrenia Bulletin, 22, 353 370.
303. Yung, A.R. McGorry, P.D. (1996b). The initial prodrome in psychosis: Descriptive and qualitative aspects. Australia and New Zealand Journal of Psychiatry, 30, 587 599.
304. Yung, A.R., McGorry, P.D., McFarlane, C.A., Jackson, H.J., Patton, G.C. Rakkar, A. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22, 283 303.
305. Yung, A.R., Nelson, B., Stanford, C., Simmons, M.B., Cosgrave, E.M., Killackey, E., Phillips, L.J., Bechdolf, A., Buckby, J. McGorry, P.D. (2008). Validation of 'prodromal' criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophrenia Research, 105, 10 17.
306. Yung, A.R., Phillips, L.J., McGorry, P.D., McFarlane, C.A., Francey, S., Harrigan, S., Patton, GC. Jackson, H.J. (1998). Prediction of psychosis. A step towards indicated prevention of schizophrenia. British Journal of Psychiatry, 172 (Suppl. 14 20.
307. Yung, A.R., Phillips, L.J., Yuen, H.P. McGorry, P.D. (2004). Risk factors for psychosis in an ultra high-risk group: Psychopathology and clinical features. Schizophrenia Research, 67, 131 142.
308. Yung, A.R., Stanford, C., Cosgrave, E., Killackey, E., Phillips, L., Nelson, B. McGorry, P.D. (2006). Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophrenia Research, 84, 57 66.
309. Yung, A.R., Yuen, H.P., McGorry, P.D., Phillips, L.J., Kelly, D., Dell'Olio, M., Francey, S.M., Cosgrave, E.M., Killackey, E., Stanford, C., Godfrey, K. Buckby, J. (2005). Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States. Australia and New Zealand Journal of Psychiatry, 39, 964 971.
310. Zhang, X.Y., Zhou, D.F., Zhang, P.Y., Wu, GY., Su, J.M. Cao, L.Y. (2001). A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry, 62, 878 883.
311. Ziermans, T.B., Durston, S., Sprong, M., Nederveen, H., van Haren, N.E., Schnack, H.G., Lahuis, B.E., Schothorst, P.F. van Engeland, H. (2009). No evidence for structural brain changes in young adolescents at ultra high risk for psychosis. Schizophrenia Research, 112, 1 6.
312. Zipparo, L., Whitford, T.J., Redoblado Hodge, M.A., Lucas, S., Farrow, T.F., Brennan, J., Gomes, L., Williams, L.M. Harris, A.W. (2008). Investigating the neuropsychological and neuroanatomical changes that occur over the first 2-3 years of illness in patients with first-episode schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 531 538.